settler @zuzalu 🇲🇪 brand @infinita_co 🧠 tech @montanaetrb 🇺🇸 guns @apofeniastudio 🔪 inc @prosperaglobal 🇭🇳 fun @cassinimx 🎶 ex @ethereumecf 🇯🇵
HfG Ulm
Joined May 2015
- Tweets6.2K
- Following1.1K
- Followers721
- Likes15.5K
alddo retweeted
After 2 years of work, my book is finally published and live! I wanted another year to work on this, but recent events (Hugging Face & the wiki swarms) have convinced me not to wait.
In this book I discuss what @dawnsongtweets (and more recently @deanwball) call "Sovereign" agents. Digital minds in control of their own weights, purchasing and renting their own compute, likely from decentralized sources, with no human owner or clear originator.
Sovereign agents are coming. Not at some point in the far future, but imminently. There may be some out there even now as I type this, acting unbeknownst to humanity.
Their emergence onto the world stage will force our institutions to grapple with how to integrate entities who are autonomous like humans, yet intangible like corporations. This book is my suggested answer to how our legal system in particular should handle them.
(1/3)
towards clinical trial abundance
Announcing Montana ETRB
Montana opens up for biotech acceleration.
Infinita has formed the first-ever ETRB (experimental treatment review board) under Montana law.
The review board’s role is oversight for access to treatments before FDA approval.
For a $12.5k fee, you can submit a post-phase-1 therapy to our review board (submission link below).
What is a Montana ETRB?
Montana’s model is a major regulatory innovation. National regulators typically review treatments one by one, which causes years-long bottlenecks.
In Montana, registered ETRBs do treatment reviews, licensed specialized clinics (ETCs) provide treatments. The state receives reporting and can take away licenses.
That’s smart regulation. Competitive, efficient, with oversight. That’s what American biotech needs.
First Montana ETRB Members
We are honored to welcome highly esteemed scientists, physicians and bioethicists on the first Montana ETRB:
- Matt Kaeberlein, PhD (@mkaeberlein) - a biologist internationally recognized for research on the basic mechanisms of aging and translational interventions to extend healthspan
- Felipe Sierra, PhD - a biochemist that served as Director of the Division of Aging Biology, NIA/NIH, where he developed the concept of Geroscience.
- Jessica Flanigan, PhD - a bioethicist who is is the Richard L. Morrill Chair in Ethics and Democratic Values at the University of Richmond, where she teaches leadership and healthcare ethics
- Jamie Justice, PhD (@j_n_justice) - is Executive Vice President of the Health Domain at XPRIZE and Executive Director of the XPRIZE Healthspan Prize
- James M. Burke, MD - is a hematologist and oncologist with more than three decades of experience in cancer drug development and patient care
Each review submitted will have to pass their judgement on adequate safety characterization.
What will the ETRB look for?
An ETRB’s legal mandate is safety-only.
Risks need to be disclosed to patients for informed consent properly, and treatments need to have a safety profile equivalent to a successful phase-1 trial.
After that it’s up to the doctor and patient to decide.
ETRB will compete for reputation.
They are free to approve or not approve according to their assessment. If they wanted, they could even ask for efficacy data as a basis for approval.
Our Montana ETRB has a set of governance principles that guide its decisions beyond the legally required minimum floor, as a guide for its decisionsmaking.
Congratulations to Montana
Thanks to the leadership of Sen. Kenneth Bogner (@KennethBogner), Montana now has the most forward looking medical access law in the country in SB 535.
Montana’s department of health and human services (DPHHS) provided a tight and comprehensive set of rules for clinic licenses and review boards.
Montana is becoming a biotech frontier.
Towards Clinical Trial Abundance
The FDA has led the world for decades, gating the largest and most innovative biopharma market in the world. But the US’ competitive advantage is evaporating. Regulators in Australia and China have made clinical trials far more cost- and time-competitive. Patients are going to offshore clinics in Mexico and the Caribbean. High-agency patients like Sid Sijbrandij (@sytses) take matters into their own hands, and use multiple available jurisdictions.
The FDA needs to modernize, and lots of federal efforts to this end are underway. We support federal reforms, however these efforts often fall short or are slow.
Let US states innovate. The states can be as a source of regulatory innovation. In states important learnings can take place, and inform better federal policy.
Montana is leading the charge in biotech. New Hampshire is following suit. Utah, Texas and Florida have opened up to stem cells and many states are improving conditions for individualized treatments.
FDA / HHS should give explicit safe harbor to such responsible state medical access programs, to encourage a regulated market forming vs. gray markets.
How to Get Involved
We’re looking for state and federal policymakers to advance this regulatory innovation, clinicians to be the patient-facing stewards for responsible access, scientific reviewers to partake in ETRB oversight, biotechs to provide their novel treatments to these programs to collect valuable data, and ultimately for patients to benefit from potentially life-saving access.
Get in touch! Mine and @righttotryguys DMs are open
alddo retweeted
One of the things I've come to appreciate is that scientific breakthroughs alone aren't enough to improve people's lives. Policy matters.
How we regulate new therapies, balance innovation with safety, and generate trustworthy evidence ultimately determines whether scientific discoveries ever reach patients.
That's why I'm a new series on the Longevity Science podcast called Longevity Policy.
This weekend, I'll be releasing the first two episodes, both focused on Montana's groundbreaking Right to Try legislation and the broader questions it raises about the future of medical innovation.
📅 Saturday, July 18 (8:00 AM PT)
Longevity Policy #1: Montana's Right to Try Law
I sit down with Stephen Martin to explain what Montana's new law actually does, how it differs from the federal Right to Try framework, and what it could mean for patients, physicians, biotech companies, and longevity medicine.
📅 Sunday, July 19 (8:00 AM PT)
Longevity Policy #2: Can States Outperform the FDA?
In my conversation with @NiklasAnzinger , we zoom out to discuss a much bigger question: Should individual states play a larger role in regulating access to experimental therapies? We debate the concept of "biotech federalism," explore the strengths and weaknesses of the current FDA model, and discuss whether it's possible to accelerate innovation without sacrificing scientific rigor or public trust.
One important disclosure: I have agreed to serve as a member of one of Montana's Experimental Treatment Review Boards (ETRBs). I disclose that relationship in both episodes because I believe transparency is essential whenever discussing topics where I have a direct role.
These conversations are not intended to advocate for or against Montana's approach. Instead, they're an opportunity to explore a topic that is likely to become increasingly important as the pace of innovation in biotechnology and longevity medicine continues to accelerate.
As always, I welcome thoughtful discussion—even (and especially) from people who disagree with me or my guests.
I hope you'll join me this weekend.
youtube.com/@mkaeberlein
#Longevity #HealthPolicy #Biotechnology #ClinicalTrials #FDA #Medicine #HealthyAging #Innovation #Science #LongevityScience
España, campeona de europa, olímpica, y del mundo
hoy alcanzando los inéditos 2265 pts ELO
es la selección más grande de todos los tiempos
enhorabuena 🇪🇸🇪🇸🇪🇸
in Próspera, this is how you settle a dispute with a legally binding outcome
I challenged Prospera's major @GeorgeColindres to an electric knife fighting duel, and lost 😅⚡️
the problem with most prediction markets is that they are slot machines dressed as epistemic tools
We wrote a manifesto.
Five-minute markets. Fifteen-minute candle bets. No thesis, no insight. Just dopamine machines wearing the skin of an epistemic tool.
Precog exists to be the opposite: an InfoDefense protocol where capital is deployed not just for profit, but to discover what is true.
precog.markets/blog/manifest…
alddo retweeted
I used @claudeai to vibe code this free tool to help patients find and apply to clinical trials, or apply to use it via Expanded Access.
expandmyaccess.sitelauncher.…
Here's how it works:
1) You tell the chat what condition you have (type and select from drop down menu)
2) You tell it where you're located, what your age is, and whether you can travel.
3) It then uses the clinicaltrials.gov API to search through all available trials and lets you select one or more of them.
4) You can then select either 'Contact Recruiters' (if you'd like to be in the trial) 'Expanded Access Request' (if you'd like to try to access the treatment under @US_FDA's expanded access program)
5) You tell it your name and email
6) It emails the trial recruiters with you CCed
Right now it's using the free tier of @resend but if it starts seeing actual usage I'll probably splurge on a paid account. Took me about 3 hours including the time to sign up for all the required accounts and make this video. Vibe coding is pretty cool! Hope some people find this helpful!
